EU Commission representative Mr. Olivér Várhelyi has outlined the Commission's approach to gain-of-function research, emphasizing stringent risk management, ethical standards, and legal compliance to prevent potential pandemic threats. His response signals a call for balancing innovative scientific inquiry with rigorous safety, aiming to reassure the public and authorities wary of high-stakes viral research. This stance will particularly resonate with health regulators, scientists, and the biotech industry, while raising scrutiny from civil society and ethical watchdogs concerned about the inherent risks.
The reply addresses a parliamentary question posed by MEP Gerald Hauser of the PfE group, who referenced former CDC head Robert Ray Redfield Jr.'s assertion that the COVID-19 pandemic may have been linked to gain-of-function research. Hauser inquired about the extent of such research within the EU, its ethical justification, and the Commission’s standpoint on SARS-CoV-2 origins.
Rather than introducing new policies or targets, the answer refers to prior parliamentary responses and existing frameworks—particularly under Horizon Europe funding—that govern eligibility, risk assessment, and adherence to ethical integrity in research. It underscores that projects with disproportionate risks to human health or the environment are ineligible for financial support, reinforcing a precautionary approach without expanding EU powers or setting fresh deadlines.
The Commission’s policy orientation leans towards maintaining current high-level supervision and legal frameworks, balancing scientific freedom with safety and accountability. This approach prioritizes strengthening ethical and security standards over loosening regulatory controls or scaling down institutional oversight.
Stakeholders affected include the EU scientific research community, which must navigate stringent compliance requirements; public health authorities, who benefit from risk-averse research governance; the biotech industry, which may face operational and financial constraints under these rules; and EU civil society organizations vigilant about pandemic prevention and ethical standards. While public health safeguards are reinforced, some research innovation may encounter hurdles due to tightened oversight.
The Commission’s answer follows Hauser’s inquiry received in February 2026 and signals ongoing institutional vigilance. Such exchanges spotlight the EU's commitment to transparency and measured governance in controversial scientific fields, with Horizon Europe serving as a key vehicle for oversight.